Financial Highlights
- Q3’26 license fee revenue rose 39% to
$1.3M , reflecting continued growth in its base of annual recurring software revenue. BIO-key has delivered meaningful year-over-year software license fee growth in each of the last three quarters. - Q3’26 total revenues were
$1.48M vs.$1.55M in Q3’25, as license fee growth largely offset lower hardware and service revenues, which have greater variability due to the timing of projects. - Q3’26 gross margin improved to 90% vs. 77% in Q3’25, reflecting the increase in high-margin license fees as a percentage of total revenue. BIO-key’s blended gross margin has increased for five consecutive quarters, from 73% in Q2’25 to 90% in Q3’26, reflecting both new customer deployments and its expanding base of annual recurring software license fees.
- Q3’26 net loss narrowed 8% to
$(886K) vs.$(965K) in Q3’25. - 9M’26 revenues grew 14% to
$5.5M , gross margin improved to 86% from 77%, and net loss improved 42% to$(1.7M) vs.$(2.9M) in 9M’25. - Working capital improved to
$3.1M at the close of Q3’26, from$1.4M at year-end 2025. - BIO-key retired its remaining note in Q3’26.
Business Outlook
- BIO-key anticipates a solid finish to 2026 and a strong start to 2027, supported by recent
Middle East government wins, a growing pipeline of government and financial sector opportunities, expanding deployments with existing customers, and anticipated annual license renewals.
Recent Progress
Middle East : BIO-key added three new government customers in October, bringing to eight the number of newMiddle East region customers in the past seven months:Portugal : Integration of BIO-key’s IAM and biometric authentication solutions into the cybersecurity portfolio of Cipher, aProsegur company, starting inPortugal – with plans to explore extending the offering to other Cipher markets, includingSpain , theU.S . andBrazil .- Agentic AI: BIO-key received
FIDO Alliance full certification for its Passkey:YOU™ authentication, opening markets where phones are restricted and supporting biometric approval of AI agent actions.
BIO-key CEO,
“The real story, however, is the customers who are choosing BIO-key, such as the
“Our momentum across
“Looking forward, the growth of artificial intelligence is also presenting opportunities as the growing commercial prevalence of AI agents creates a new identity challenge. Industry research suggests that machine identities, including AI agents, already outnumber human identities by more than 100 to 1. To address this trend, the
“Our recent wins and a growing pipeline of government and banking opportunities across EMEA position us for a strong finish to 2026. More importantly, we believe the foundation we are building today, with marquee government and financial customers, growing high-margin software revenue, a streamlined cost structure and a cleaner balance sheet, sets the stage for an exciting 2027.”
Financial Review
Total revenues were
Q3’26 hardware revenues were
Q3’26 gross profit increased 12% to
BIO-key’s Q3’26 operating expenses increased 4% to
Reflecting higher gross profit, BIO-key’s Q3’26 operating loss improved to
Also reflecting higher revenue and gross profit and lower operating expenses, BIO-key’s 9M’26 net loss improved 42% to
Balance Sheet
BIO-key’s stockholders’ equity improved to
As of
During Q3, BIO-key retired the remaining balance of its note payable, through exchanges for common stock leaving the company effectively free of debt, other than a
Call/Webcast Detail
| Date / Time: | |
| Call Dial In #: | 1-877-418-5460 |
| Live Webcast / Replay: | Webcast & Replay Link – Available for 3 months. |
| Audio Replay: | 1-855-669-9658 |
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is a global provider of biometric-centric Identity and Access Management (IAM) and authentication solutions, securing access for over forty million users across government, defense, financial services and enterprise customers. Its PortalGuard IAM platform, Identity-Bound Biometrics and FIDO-certified Passkey:YOU authentication give organizations flexible phoneless, tokenless and passwordless options to secure access to computers, applications, information and high-value transactions, whether cloud-hosted or on-premise.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of non-compliance with Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements due to late filings; the commercial and reputational risk and impact on the trading and liquidity of our common stock due to the recent suspension of trading of our common stock on the Nasdaq Capital Market from May 13, 2026 until its reinstatement effective July 8, 2026, the monitoring of our compliance by the Nasdaq Hearing Panel through July 6, 2027, or in the event that the trading of our common stock is suspended due to non-compliance with existing and/or proposed continued listing standards of the Nasdaq Stock Market; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to continue to maintain effective internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K/A for the year ended December 31, 2025 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
| Engage with BIO-key | |
| Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ |
| LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international |
| X – Corporate: | @BIOkeyIntl |
| X – Investors: | @BIO_keyIR |
| BIO_keyIR | |
Investor Contacts
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | ||||||||||||||||
| Services | $ | 195,128 | $ | 268,113 | $ | 674,516 | $ | 862,707 | ||||||||
| License fees | 1,275,249 | 917,951 | 3,870,487 | 2,822,796 | ||||||||||||
| Hardware | 12,404 | 363,642 | 1,003,302 | 1,168,269 | ||||||||||||
| Total revenues | 1,482,781 | 1,549,706 | 5,548,305 | 4,853,772 | ||||||||||||
| Costs and other expenses | ||||||||||||||||
| Cost of services | 76,704 | 80,702 | 234,918 | 297,147 | ||||||||||||
| Cost of license fees | 55,953 | 74,077 | 204,159 | 233,450 | ||||||||||||
| Cost of hardware | 15,184 | 434,834 | 1,133,035 | 1,080,109 | ||||||||||||
| Cost of hardware - reserve | (4,468 | ) | (231,625 | ) | (806,488 | ) | (509,040 | ) | ||||||||
| Total costs and other expenses | 143,373 | 357,988 | 765,624 | 1,101,666 | ||||||||||||
| Gross profit | 1,339,408 | 1,191,718 | 4,782,681 | 3,752,106 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 1,524,583 | 1,400,288 | 4,397,676 | 4,453,362 | ||||||||||||
| Research, development and engineering | 635,038 | 683,620 | 1,892,337 | 1,915,422 | ||||||||||||
| Total operating expenses | 2,159,621 | 2,083,908 | 6,290,013 | 6,368,784 | ||||||||||||
| Operating loss | (820,213 | ) | (892,190 | ) | (1,507,332 | ) | (2,616,678 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 678 | 515 | 1,740 | 2,610 | ||||||||||||
| Loan fee amortization | (62,500 | ) | (60,000 | ) | (104,166 | ) | (180,000 | ) | ||||||||
| Interest expense | (4,048 | ) | (13,174 | ) | (58,214 | ) | (74,722 | ) | ||||||||
| Total other income (expense), net | (65,870 | ) | (72,659 | ) | (160,640 | ) | (252,112 | ) | ||||||||
| Loss before provision for income tax | (886,083 | ) | (964,849 | ) | (1,667,972 | ) | (2,868,790 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (886,083 | ) | $ | (964,849 | ) | $ | (1,667,972 | ) | $ | (2,868,790 | ) | ||||
| Deemed dividend related to warrant inducement | (4,502,004 | ) | - | (4,502,004 | ) | - | ||||||||||
| Net loss available to common stockholders | $ | (5,388,087 | ) | $ | (964,849 | ) | $ | (6,169,976 | ) | $ | (2,868,790 | ) | ||||
| Comprehensive loss: | ||||||||||||||||
| Net loss available to common stockholders | $ | (5,388,087 | ) | $ | (964,849 | ) | $ | (6,169,976 | ) | $ | (2,868,790 | ) | ||||
| Other comprehensive loss – foreign currency translation adjustment | (62,409 | ) | (73,910 | ) | (143,503 | ) | (8,302 | ) | ||||||||
| Comprehensive loss | $ | (5,450,496 | ) | $ | (1,038,759 | ) | $ | (6,313,479 | ) | $ | (2,877,092 | ) | ||||
| Basic and diluted loss per common share | $ | (4.01 | ) | $ | (1.44 | ) | $ | (5.37 | ) | $ | (4.87 | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic and diluted | 1,342,766 | 671,820 | 1,147,994 | 588,474 | ||||||||||||
| All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective | ||||||||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 2,219,428 | $ | 2,694,663 | ||||
| Accounts receivable, net | 2,354,935 | 1,220,822 | ||||||
| Inventory | 367,063 | 370,879 | ||||||
| Prepaid expenses and other | 337,445 | 251,323 | ||||||
| Total current assets | 5,278,871 | 4,537,687 | ||||||
| Equipment and leasehold improvements, net | 32,051 | 67,751 | ||||||
| Capitalized contract costs, net | 229,599 | 311,591 | ||||||
| Deposits and other assets | 7,976 | 7,976 | ||||||
| Operating lease right-of-use assets | 132,603 | 47,953 | ||||||
| Investments | 2,500,000 | 2,500,000 | ||||||
| Intangible assets, net | 662,572 | 830,357 | ||||||
| Total non-current assets | 3,564,801 | 3,765,628 | ||||||
| TOTAL ASSETS | $ | 8,843,672 | $ | 8,303,315 | ||||
| LIABILITIES | ||||||||
| Accounts payable | $ | 321,809 | $ | 507,357 | ||||
| Accrued liabilities | 1,194,591 | 1,333,930 | ||||||
| Note payable | - | 604,102 | ||||||
| Government loan – BBVA Bank, current portion | 12,351 | 50,530 | ||||||
| Deferred revenue, current | 542,486 | 572,513 | ||||||
| Operating lease liabilities, current portion | 67,735 | 27,728 | ||||||
| Total current liabilities | 2,138,972 | 3,096,160 | ||||||
| Deferred revenue, long term | 80,694 | 62,584 | ||||||
| Deferred tax liability | 16,500 | 16,500 | ||||||
| Operating lease liabilities, net of current portion | 65,864 | 21,266 | ||||||
| Total non-current liabilities | 163,058 | 100,350 | ||||||
| TOTAL LIABILITIES | 2,302,030 | 3,196,510 | ||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 2,035,149 of respectively | 204 | 109 | ||||||
| Additional paid-in capital | 149,245,962 | 141,497,741 | ||||||
| Accumulated other comprehensive income (loss) | (68,700 | ) | 74,803 | |||||
| Accumulated deficit | (142,635,824 | ) | (136,465,848 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 6,541,642 | 5,106,805 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 8,843,672 | $ | 8,303,315 | ||||
| All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective | ||||||||
Source: 